H Plus Yangji Hospital Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial
2020
NCT04780386
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

H Plus Yangji Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyslipidemias (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 7
  • # of Trial APIs: 11